<p>Pharming Group（OTCMKTS:PHGUF - 获取免费报告）于周四发布了季度财报。这家生物技术公司报告的每股收益（EPS）为（$0.01），据 Zacks 报道。Pharming Group 的股本回报率为 4.68%，净利润率为 3.30%。该公司本季度的收入为 7245 万美元，而分析师预计为 9206 万美元。</p>
<p>获取 <strong>Pharming Group</strong> 警报：</p>
<h2>Pharming Group 股票表现</h2>
<p>周五中午交易时，Pharming Group 的股票价格保持在$1.25。该公司交易了 5,071 股股票，而其平均交易量为 390 股。Pharming Group 的股价一年低点为$0.96，一年高点为$2.17。该公司的市值为 8.3696 亿美元，市盈率为 62.39，贝塔值为 0.55。该股票的 50 日移动平均线为$1.60，200 日移动平均线为$1.65。该公司的速动比率为 2.03，流动比率为 2.59，债务与股本比率为 0.39。</p>
<h2>Pharming Group 公司简介</h2>
<p>（获取免费报告）</p>
<p>Pharming Group NV 是一家总部位于荷兰的生物制药公司，专注于为罕见疾病开发和商业化蛋白质替代疗法。公司成立于 1988 年，总部位于莱顿，利用转基因技术生产重组蛋白，其旗舰产品 RUCONEST（重组 C1 酯酶抑制剂）用于治疗急性遗传性血管水肿（HAE）发作。RUCONEST 已在美国、欧洲及其他多个地区获得批准并通过与领先的专业制药公司合作进行市场推广。</p>
<p>除了 RUCONEST，Pharming 还保持着多样化的产品线，针对罕见和超罕见疾病的未满足需求。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Pharming Group</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Pharming Group 吗？</h2>
<p>在考虑 Pharming Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Pharming Group 并不在名单上。</p>
<p>虽然 Pharming Group 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PHAR

医药突破 ETF - ALPS

IBBQ

<p>Pharming Group (OTCMKTS:PHGUF) 发布了季度财报，显示每股收益亏损为 ($0.01)，收入为 7245 万美元，低于分析师预期的 9206 万美元。该公司的股本回报率为 4.68%，净利润率为 3.30%。Pharming 的股票保持在 1.25 美元，市值为 8.3696 亿美元。该公司专注于罕见疾病的蛋白质替代疗法，其主要产品 RUCONEST 已在多个地区获得批准</p>

<p>Pharming Group (OTCMKTS:PHGUF - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.</p>
<div class="lb-trans"><p>Pharming Group（OTCMKTS:PHGUF - 获取免费报告）于周四发布了季度财报。这家生物技术公司报告的每股收益（EPS）为（$0.01），据 Zacks 报道。Pharming Group 的股本回报率为 4.68%，净利润率为 3.30%。该公司本季度的收入为 7245 万美元，而分析师预计为 9206 万美元。</p>
</div><p>Get <strong>Pharming Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pharming Group</strong> 警报：</p>
</div><h2>Pharming Group Stock Performance</h2>
<div class="lb-trans"><h2>Pharming Group 股票表现</h2>
</div><p>Shares of Pharming Group stock remained flat at $1.25 during mid-day trading on Friday. 5,071 shares of the company's stock traded hands, compared to its average volume of 390. Pharming Group has a one year low of $0.96 and a one year high of $2.17. The company has a market cap of $836.96 million, a PE ratio of 62.39 and a beta of 0.55. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.65. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.39.</p>
<div class="lb-trans"><p>周五中午交易时，Pharming Group 的股票价格保持在$1.25。该公司交易了 5,071 股股票，而其平均交易量为 390 股。Pharming Group 的股价一年低点为$0.96，一年高点为$2.17。该公司的市值为 8.3696 亿美元，市盈率为 62.39，贝塔值为 0.55。该股票的 50 日移动平均线为$1.60，200 日移动平均线为$1.65。该公司的速动比率为 2.03，流动比率为 2.59，债务与股本比率为 0.39。</p>
</div><h2>Pharming Group Company Profile</h2>
<div class="lb-trans"><h2>Pharming Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.</p>
<div class="lb-trans"><p>Pharming Group NV 是一家总部位于荷兰的生物制药公司，专注于为罕见疾病开发和商业化蛋白质替代疗法。公司成立于 1988 年，总部位于莱顿，利用转基因技术生产重组蛋白，其旗舰产品 RUCONEST（重组 C1 酯酶抑制剂）用于治疗急性遗传性血管水肿（HAE）发作。RUCONEST 已在美国、欧洲及其他多个地区获得批准并通过与领先的专业制药公司合作进行市场推广。</p>
</div><p>Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.</p>
<div class="lb-trans"><p>除了 RUCONEST，Pharming 还保持着多样化的产品线，针对罕见和超罕见疾病的未满足需求。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Pharming Group</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Pharming Group</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=OTCMKTS&amp;Symbol=PHGUF"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pharming Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Pharming Group 吗？</h2>
</div><p>Before you consider Pharming Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Pharming Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Pharming Group 并不在名单上。</p>
</div><p>While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pharming Group 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pharming Group (OTCMKTS:PHGUF) 公布季度财报结果